Fine needle aspiration biopsy (FNAB) has established itself as a safe and r
eliable diagnostic modality that is now routinely employed in the evaluatio
n of endocrine tumors. Although FNAB provides specific diagnoses in the maj
ority of cases, certain processes may not be readily distinguished by cytom
orphology alone. Akin to the contributions of immunochemistry to diagnostic
pathology, molecular diagnostics is now becoming an integral part of patie
nt management. Molecular pathology may provide information regarding the di
agnosis, prognosis, and therapy of numerous lesions. It is anticipated that
further research and improvements in technology will result in the develop
ment of sensitive and specific tests that will enhance the management of th
e endocrine patient.